Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Fortress Biotech ( (FBIO) ) has shared an update.
On July 16, 2025, AstraZeneca announced that its Phase III clinical trial for anselamimab, a treatment for AL amyloidosis originally developed by Caelum Biosciences, did not achieve statistical significance for its primary endpoint in certain patient stages. Despite this, the drug showed clinically meaningful improvements in a specific subgroup and was well tolerated, prompting AstraZeneca to continue evaluating the results and plan further discussions with global health authorities.
The most recent analyst rating on (FBIO) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.
Spark’s Take on FBIO Stock
According to Spark, TipRanks’ AI Analyst, FBIO is a Neutral.
Fortress Biotech’s overall score is primarily affected by its poor financial performance, characterized by negative earnings and high leverage. Although a recent merger provides a positive outlook for future cash inflows, technical indicators are neutral, and valuation metrics are weak due to negative earnings. The merger event slightly improves the outlook, but significant financial challenges remain.
To see Spark’s full report on FBIO stock, click here.
More about Fortress Biotech
Fortress Biotech, Inc. is a biopharmaceutical company involved in the development and commercialization of innovative pharmaceutical products. It has a focus on creating and acquiring promising therapeutic candidates, as demonstrated by its founding of Caelum Biosciences, which developed the product candidate anselamimab for the treatment of light chain (AL) amyloidosis.
Average Trading Volume: 202,480
Technical Sentiment Signal: Hold
Current Market Cap: $57.96M
For a thorough assessment of FBIO stock, go to TipRanks’ Stock Analysis page.